A NOVEL TRANSMUCOSAL DELIVERY SYSTEM

The novel trans mucosal dosage form of this invention relates. to -benzimidazole class of proton pump inhibitors and their precursors, derivatives or salts for the delivery of the drugs in the oral cavity. The novel transmucosal dosage forms do not require enteric coating, or any other coating or ex...

Full description

Saved in:
Bibliographic Details
Main Authors DEVARAJAN, PADMA, VENKITACHALAM, MAHESHWARI, KIRTI, BANSIDHAR, MANDAL, JAYANTA, KUMAR, PATEL, SHASHANK, BABABHAI
Format Patent
LanguageEnglish
French
Published 14.04.2005
Edition7
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The novel trans mucosal dosage form of this invention relates. to -benzimidazole class of proton pump inhibitors and their precursors, derivatives or salts for the delivery of the drugs in the oral cavity. The novel transmucosal dosage forms do not require enteric coating, or any other coating or excess sodium ions commonly employed for this class of drugs. Commonly used site of absoq.)tion for this invention relates to sublingual, gingival or other oral mucosa. L'invention concerne une nouvelle forme dosifiée transmucosale qui comprend la classe des benzimidazoles d'inhibiteurs de pompe à protons et leurs précurseurs, dérivés ou sels destinés à l'administration des médicaments dans la cavité buccale. Ces nouvelles formes dosifiées transmucosales ne requièrent pas un revêtement entérique ou tout autre revêtement ou ions de sodium en excès généralement utilisés dans cette classe de médicaments. D'autres sites généralement utilisés dans cette invention englobent la muqueuse sublinguale, gingivale ou toute autre muqueuse buccale.
Bibliography:Application Number: WO2004IN00013